ArticleAnnals of the rheumatic diseases2020
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 5 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Individual risk factors associated with SARS-CoV-2 infection during Alpha variant in high-income countries: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature.Turkish journal of medical sciences · 2022Pooled it
- Pooled it
- SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis.Arthritis & rheumatology (Hoboken, N.J.) · 2022Pooled it
- Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.Rheumatology international · 2021Pooled it
- Association between COVID-19 infection and uveitis flare in patients with Behcet's disease, a retrospective multicenter cohort study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Pandemic of the century: COVID-19 in inflammatory rheumatic diseases of a national cohort with 3,532 patients.Archives of rheumatology · 2024Article
- Article
- Article
- Knowledge mapping of COVID-19 and autoimmune diseases: a visual and bibliometric analysis.Clinical and experimental medicine · 2023Article
- COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour.Modern rheumatology · 2023Article
- Photoacoustic Imaging of COVID-19 Vaccine Site Inflammation of Autoimmune Disease Patients.Sensors (Basel, Switzerland) · 2023Article
- Association between COVID-19 and chronic liver disease: Mechanism, diagnosis, damage, and treatment.World journal of virology · 2023Review
- SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.Frontiers in immunology · 2023Observational
- Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses.Clinical rheumatology · 2022Review
- Endothelialitis, Microischemia, and Intussusceptive Angiogenesis in COVID-19.Cold Spring Harbor perspectives in medicine · 2022Review
- Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry.ACR open rheumatology · 2022Article
- Characteristics of COVID-19 Infection in a Hospitalized Autoimmune Hepatitis Patient.Pathogens (Basel, Switzerland) · 2022Article
- Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management.Clinical rheumatology · 2022Review
- Humoral and cellular response in convalescent COVID-19 lupus patients.Scientific reports · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.
methodsWe performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups.
resultsPatients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution.
conclusionPatients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.